Decision

Eli Lilly Canada Inc. v. Novopharm Limited, 2013 FC 677 (Olanzapine*)

Proth. Tabib - 2013-06-18

Read full decision. Automatically generated summary:

By the present motion, the Defendant/Plaintiff by Counterclaim, Teva Canada Limited ("Teva") seeks to amend its Statement of Defence and Counterclaim after the first phase of this bifurcated action has been heard and determined in its favour, but before the start of discoveries on the second phase of the litigation.

Decision relates to:

  • T-1048-07 - ELI LILLY CANADA INC. ET AL v. NOVOPHARM LIMITED

 

Canadian Intellectual Property